University of Saskatchewan academics

ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin® Softgel Capsules for Advanced Cancer Pain Management

Retrieved on: 
Tuesday, December 5, 2023
Research, Cannabis, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Natural Resources, Oncology, Arm, University of Saskatchewan academics, Safety, Clinical trial, Pain management, Patient, Division, University, Cancer, Pain, Quality of life, Pharmaceutical industry

ZYUS Life Sciences Corporation ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, announced today it has made the strategic decision to proceed with a Phase 2 Clinical Trial in Canada to assess the preliminary efficacy, safety and tolerability of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

Key Points: 
  • ZYUS Life Sciences Corporation ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, announced today it has made the strategic decision to proceed with a Phase 2 Clinical Trial in Canada to assess the preliminary efficacy, safety and tolerability of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.
  • “This Phase 2 Clinical Trial is a landmark moment in ZYUS’ mission to reimagine the treatment of pain by redefining the standard of care with the development of cannabinoid-based therapies for pain management in pursuit of transformational impact on patients’ lives.”
    Initially planned as a Phase 2a Clinical Trial, ZYUS has made the strategic decision to fast-track and progress directly to a full Phase 2 Clinical Trial following receipt of positive results from its Phase 1, first-in-human clinical trial testing the safety and tolerability of Trichomylin softgel capsules.
  • ZYUS has selected a leading, full-service Canadian contract research organization with extensive clinical trial management experience to conduct its Phase 2 Clinical Trial.
  • As a cancer specialist, Dr. Stakiw has extensive clinical trial experience and has served as primary investigator of numerous clinical trials.

Baszucki Group Hires Ontario Brain Institute Executive, Kirk Nylen, PhD, to Lead Neuroscience Program

Retrieved on: 
Tuesday, September 26, 2023
Epilepsy, Informatics, BA, University, Toronto International Film Festival Changemaker Award, Policy, University of Saskatchewan academics, DSM-IV codes, Ontario Science Centre, European Institute of Innovation and Technology, Innovation, Research, Doctor of Philosophy, European Institute, EIT, Milken Institute School of Public Health, Metabolism, Patient, Trustee, SAN, Master of Science, Milken Institute, Pharmacology, Psychiatry, Roblox, Nursing, Neuroscience

SAN MATEO, Calif., Sept. 26, 2023 /PRNewswire/ -- Baszucki Group today announced it has hired Kirk Nylen, PhD, as Managing Director, Neuroscience to oversee its growing research program. Prior to joining Baszucki Group, Dr. Nylen served as a Deputy Scientific Director and Vice President of Integrated Discovery & Informatics at the Ontario Brain Institute.

Key Points: 
  • SAN MATEO, Calif., Sept. 26, 2023 /PRNewswire/ -- Baszucki Group today announced it has hired Kirk Nylen, PhD, as Managing Director, Neuroscience to oversee its growing research program.
  • Prior to joining Baszucki Group, Dr. Nylen served as a Deputy Scientific Director and Vice President of Integrated Discovery & Informatics at the Ontario Brain Institute.
  • Dr. Nylen will leverage his experience in metabolic neuroscience and open data research networks to advance Baszucki Group's mission to transform mental health outcomes.
  • "We are witnessing a sea change in how we study and treat mental illness," said Jan Ellison Baszucki, who co-founded Baszucki Group with Roblox founder and CEO, David Baszucki, in 2021.

New research may point the way towards frost-free heat pumps

Retrieved on: 
Tuesday, September 5, 2023
University, Magic, Atmosphere, Solution, University of Saskatchewan academics, Eco-friendly dentistry, Research, Science, Membrane, Frost, Ice, Freezing, Risk, Frustration, Physics, Heat, Wood drying, Heating, ventilation, and air conditioning, Viticulture

In buildings, frosting is a problem that impacts several systems, including heat pumps that keep indoor spaces warm.

Key Points: 
  • In buildings, frosting is a problem that impacts several systems, including heat pumps that keep indoor spaces warm.
  • Researchers at the University of Saskatchewan are working to eliminate this chilly scenario by creating frost-resistant heat pumps.
  • Heat pumps electrify heating and play a pivotal role in our quest for energy efficiency and eco-friendliness, owing to their relatively high efficiencies.
  • Ongoing research
    A major part of the ongoing endeavours to develop frost-free heat pumps has roots in research into frost-free energy exchangers.

GIFS researcher supports international team effort to sequence earliest domesticated wheat genome

Retrieved on: 
Wednesday, August 30, 2023
Food security, Biotechnology, University, European Research Council, Genetics, Breeding, Disease resistance, University of Saskatchewan academics, Whole wheat bread, Research, Genomics, Doctor of Philosophy, The Global Institute for Tomorrow, Biology, Wheat, Knowledge, Gene, King Abdullah University of Science and Technology, Consejo Nacional de Ciencia y Tecnología (Mexico), OPAL, Cereal, Agriculture, Nature

More than two dozen scientists have contributed to a project that that has sequenced and characterized genomes of wild and domesticated einkorn, the world’s first domesticated wheat species.

Key Points: 
  • More than two dozen scientists have contributed to a project that that has sequenced and characterized genomes of wild and domesticated einkorn, the world’s first domesticated wheat species.
  • “Though significant advances have been made in wheat species genomics, the species Triticum monococum (einkorn), representing the earliest domesticated wheat, was not defined yet,” said Datla.
  • “The insights gained from genome sequencing wild and domesticated accessions allow us to reconstruct the origin and evolution of einkorn,” said Datla.
  • In 2020, a team, led by USask’s Dr. Curtis Pozniak (PhD), sequenced the genomes for 15 different wheat varieties.

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

Retrieved on: 
Tuesday, August 22, 2023
ASPR, Defence Research and Development Canada, Cell biology, CSE, University, Biomedical Advanced Research and Development Authority, Therapy, Biochemistry, Doctor of Philosophy, HHS, U.S. Department of Defense Strategy for Operating in Cyberspace, Public, Office of Inspector General, U.S. Department of Health and Human Services, University of Saskatchewan academics, Injury, Research, Infection, Postgraduate education, Central Department of Chemistry, Tribhuvan University, Disorder, DRDC, Assistant, Inflammation, RVV, Development, Graduate, Administration, Organ transplantation, Administration for Strategic Preparedness and Response, Acute respiratory distress syndrome, FDA, BARDA, Dean (education), Pharmaceutical industry, Science, Bucillamine

In addition, the Company may explore the use of the novel Bucillamine formulation as a potent antioxidant and anti-inflammatory treatment for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury resulting from solid organ transplantation.

Key Points: 
  • In addition, the Company may explore the use of the novel Bucillamine formulation as a potent antioxidant and anti-inflammatory treatment for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury resulting from solid organ transplantation.
  • The Company has entered into a sponsored research agreement with the University of Waterloo to develop a novel lyophilized Bucillamine injectable formulation for public health medical emergencies and rare inflammatory disorders.
  • Upon completion of the formulation development, which is expected by end-2023, the Company will seek to initiate research studies in line with the Company’s commitment to advancing the clinical and commercial development of Bucillamine through the following strategic initiatives:
    Target Indications: Novel Bucillamine in an injectable version to expand on its potential therapeutic utility targeting rare disorders such as ischemia-reperfusion injury (i.e.
  • At this time, the Company will only provide regular updates via press releases as information becomes available.

Government of Canada Announces Federal Support for Small Modular Reactor (SMR) Development in Saskatchewan

Retrieved on: 
Saturday, August 19, 2023
Sulfur, United States Senate Committee on Energy and Natural Resources, The Conference Board, Partnership, University, E.B. Campbell Hydroelectric Station, Electricity, University of Saskatchewan academics, Uranium, GE Hitachi Nuclear Energy, GE, Ontario Power Generation, Climate change, Mercury, ECCC, Government, Natural Resources Canada, Science, Natural Resources, Pollutant, Air pollution, Coal, Rolls-Royce SMR, Death, Gross domestic product, Cowessess First Nation, Investment, Conference, Economic development, Natural gas, Particulates, Local government in Canada, SMR, SaskPower, Environment, Nitrogen, Health Canada, Greenhouse, News, Disease, Renewable energy

That is why the Government of Canada is committing up to $74 million to explore the potential for small modular reactors in Saskatchewan to provide abundant non-emitting power, drive economic growth and create good jobs throughout Saskatchewan.

Key Points: 
  • That is why the Government of Canada is committing up to $74 million to explore the potential for small modular reactors in Saskatchewan to provide abundant non-emitting power, drive economic growth and create good jobs throughout Saskatchewan.
  • "GE Hitachi is excited to work with Saskatchewan to be a global leader in the deployment of small modular reactors.
  • The fund is intended to help spur innovation and encourage the adoption of cleaner technologies and fuels in Canada — including Saskatchewan's small modular reactor project.
  • In July 2022, the Government of Canada invested almost $10 million in clean energy support for Indigenous communities in Saskatchewan.

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Retrieved on: 
Wednesday, July 5, 2023
Acceleration, Operation, IPO, Drug development, University, Edwards School of Business, Diabetes, Senior, Chief business officer, University of Saskatchewan academics, Cancer, Business, NK, PwC, Economics, Patient, SAN, Vertex Pharmaceuticals, Growth, Management, Psychology

SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of Alyssa Levin as Chief Financial and Business Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of Alyssa Levin as Chief Financial and Business Officer.
  • I’m excited to partner with the team at Nkarta to build a world class cell therapy development company.”
    Ms. Levin joins Nkarta from Viacyte, a biotechnology company developing stem cell therapy for diabetes, where she oversaw financial strategy and planning as Chief Financial Officer and led the company’s successful merger with Vertex Pharmaceuticals in 2022.
  • Previously, Ms. Levin was Chief Financial Officer and Senior Vice President of Operations at Tentarix Biotherapeutics from 2020 to 2022, and Chief Financial Officer at Bird Rock Bio, Inc. from 2019 to 2020.
  • Immediately prior to her start as Chief Financial and Business Officer of Nkarta, Ms. Levin served as a consultant to the company.

Quarterhill Announces CFO Departure

Retrieved on: 
Wednesday, May 24, 2023
LLP, Interim, AutoCanada, University, Toronto Stock Exchange, University of Saskatchewan academics, Interim management, KPMG LLP, ITS, CPA, TSX, Growth, McLane Advanced Technologies, Chartered Professional Accountant, KPMG, Commerce, Ministry of Finance, Management

TORONTO, May 24, 2023 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF) announces that John Karnes, Chief Financial Officer ("CFO"), is departing the Company and Kyle Chriest, VP Corporate Finance, has been appointed Interim CFO.

Key Points: 
  • TORONTO, May 24, 2023 /PRNewswire/ - Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF) announces that John Karnes, Chief Financial Officer ("CFO"), is departing the Company and Kyle Chriest, VP Corporate Finance, has been appointed Interim CFO.
  • Mr. Chriest joined Quarterhill in November 2022.
  • During Kyle's time with Calian, the company experienced significant organic and inorganic growth, with revenue growing from $250 million to $500 million.
  • Prior to that, Mr Chriest held a variety of accounting roles at AutoCanada, KPMG LLP and Deloitte and Touche LLP.

Traction Uranium Hearty Bay Research Program Indicates Historical Exposure to Uranium Bearing Fluids in 3 Boreholes

Retrieved on: 
Wednesday, April 26, 2023
Astrogeology Research Program, Quartz, TRAC, Radiation, CSE, University, Powder, Annette Rid, Research program, 3D, EM, Thorium, University of Saskatchewan academics, Uranium, Athabasca Basin, Research, McArthur, FRA, 2D, Traction, Key Lake mine, PXRD, Documentation, EPR, NE, Alpha, Water, OTC, Isle, Isotope, Athabasca, CL, News, Uranium mining, Granite, Medical imaging

The main purpose of the Research Program is to assist the Company in determining whether there was uranium-bearing fluids within a target area and to help Traction’s team define and trace the conduit(s) of any such uranium-bearing fluids.

Key Points: 
  • The main purpose of the Research Program is to assist the Company in determining whether there was uranium-bearing fluids within a target area and to help Traction’s team define and trace the conduit(s) of any such uranium-bearing fluids.
  • Reference sample from the McArthur and Mann Lake uranium deposits was used as a comparative standard.
  • The main analytical techniques used for the Research Program are cathodoluminescence (“CL”) imaging and electron paramagnetic resonance (“EPR”) spectroscopy.
  • The separated quartz grains were pulverized into powders, which were checked for purity by powder X-ray diffraction (PXRD) analyses.

The Government of Canada to invest over $2.1 million in wildlife disease surveillance across the country

Retrieved on: 
Thursday, February 9, 2023
Government of Canada Building (North York), Environment, Infection, Government, Climate change, University of Saskatchewan, Virus, Animal, Veterinary medicine, Chronic wasting disease, Maintenance, Environment and Climate Change Canada, University of Calgary Faculty of Veterinary Medicine, Ontario Veterinary College, Face, University, Health, Little brown bat, Wildlife disease, The Honourable, Habitat, Western College of Veterinary Medicine, Knowledge, Food security, Atlantic Veterinary College, Journal of Wildlife Diseases, Education, White-nose syndrome, Zoonosis, Data management, University of Saskatchewan academics, COVID-19, Hunting, Pharmaceutical industry, Vaccine, Agriculture, Food, QC

The projects are being led by the national office of the Canadian Wildlife Health Cooperative, based at the University of Saskatchewan.

Key Points: 
  • The projects are being led by the national office of the Canadian Wildlife Health Cooperative, based at the University of Saskatchewan.
  • These projects include the development of new tools to track wildlife health and the risks of emerging infectious diseases.
  • Work is also planned for identifying and predicting the impacts of climate change on wildlife health and will include avenues for action.
  • The Canadian Wildlife Health Cooperative brings together internationally recognized wildlife health researchers and diagnosticians, population health experts, and experienced educators.